论文部分内容阅读
应用抗ＨＣＶ酶联免疫分析（ＥＩＡ）试验药盒对２４０例消化系统等疾病作抗ＨＣＶ测定，其中慢性迁延性肝炎３１例、慢性活动性肝炎１９例、失代偿期肝硬变５８例、原发性肝癌５０例、慢性浅表性胃炎１０例、消化性溃疡１３例、进展期胃癌１１例、血液透析者３１例，以及其他消化系疾病１７例。另外，４１例健康献血员作为对照组。各组血清抗ＨＣＶ阳性率分别为３５．４％、３１．６％、８．６％、１０．０％、０．０％、１５．４％、１８．２％、６４．５％。０．０％及４．９％。本组血液透析患者血清抗ＨＣＶ检出率明显增高。因此，对健康献血员在作肝功能及ＨＢＶ系列测定的同时应作抗ＨＣＶ测定，对血清抗ＨＣＶ阳性者进行积极的治疗。
Anti-HCV assay was performed in 240 digestive diseases and other diseases by anti-HCV enzyme-linked immunosorbent assay (EIA) test kit, including 31 cases of chronic persistent hepatitis, 19 cases of chronic active hepatitis, 58 cases of decompensated cirrhosis, 50 cases of primary liver cancer, 10 cases of chronic superficial gastritis, peptic ulcer in 13 cases, advanced gastric cancer in 11 cases, hemodialysis in 31 cases, and other gastrointestinal diseases in 17 cases. In addition, 41 healthy blood donors served as controls. The positive rates of serum anti-HCV in each group were 35.4%, 31.6%, 8.6%, 10.0%, 0.0%, 15.4%, 18.2%, 64.5% respectively. 0.0% and 4.9%. This group of patients with hemodialysis serum anti-HCV detection rate was significantly higher. Therefore, healthy blood donors in the determination of liver function and HBV series should also be anti-HCV assay, the positive anti-HCV serum for active treatment.